NY-CALVIN-KLEIN-INC
3.8.2020 13:02:08 CEST | Business Wire | Press release
Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. [NYSE: PVH], and Calvin Klein Fragrances, a division of Coty Inc. [NYSE: COTY], today revealed the worldwide global advertising campaign for ETERNITY Calvin Klein with the return of maternal health activist and model Christy Turlington Burns, alongside her husband, director, writer, producer and actor Edward Burns, as the faces of the ETERNITY campaign.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200803005090/en/
ETERNITY Calvin Klein advertising has artfully and unforgettably captured the promise of romance, intimacy, and commitment. Together, Turlington Burns who starred in the first ETERNITY advertising campaign when it debuted in 1988, and Burns who has appeared next to his wife in the 2014 and 2016 campaigns, bring to life the essence of the ETERNITY love story with their timeless relationship.
Today, the ETERNITY story continues with the iconic couple in a new television and print campaign that portrays an enduring love rooted in sensuality, authenticity, spontaneity, and supports the launch of the new ETERNITY Cologne for him and ETERNITY Eau Fresh for her Calvin Klein.
“After shooting the first ETERNITY Calvin Klein campaign ever over 30 years ago, it’s a pleasure to be working with Calvin Klein again and to continue to be a part of the history of such an iconic fragrance,” said Turlington Burns + Burns jointly. “We are honored to be part of this new campaign celebrating our relationship with ETERNITY Calvin Klein.”
The television campaign is captured by filmmaker and photographer Matt Lambert and is a combination of traditional black and white in addition to color shots. This juxtaposition conveys their committed past with the strength of their present relationship. The campaign, a compilation of joyful moments by the ocean, is an homage to their love story and is set to a reimagined cover of the iconic love song ‘Unchained Melody’ by Lykke Li.
Lachlan Bailey photographed the iconic couple in a classic black and white still campaign visual on the beach. Turlington Burns' hair is effortlessly being swept back by the ocean breeze while Burns adoringly pulls her toward him. The image is just one of many memories in time for the couple, a stolen moment in their endless love story.
“We are thrilled to welcome back such an iconic couple to celebrate the next chapter of ETERNITY Calvin Klein which continues its legacy as one of the most beloved fragrances for both men and women,” said Simona Cattaneo, President of Luxury Brands at Coty. “With this new campaign ETERNITY continues to inspire timeless love; its romantic values are undimmed by the passing of time and still resonate with consumers today.”
In addition to supporting ETERNITY Calvin Klein Signature, the campaign also supports the new line extension ETERNITY Cologne for him and ETERNITY Eau Fresh for her Calvin Klein through the still campaign visual also shot by Bailey. The hero image is an injection of happiness and bursts of freshness; Turlington Burns and Burns are captured playfully frolicking in the ocean, holding each other closely as the waves splash around them.
Evoking the free-spirited nature of the ocean and the joy of strolling through a beautiful sensual garden, the line extension inspires spontaneity while celebrating the spirit of eternal love. The enduring legacy of the ETERNITY Calvin Klein Signature is playfully reimagined for modern lovers with fresh green ingredients in ETERNITY Cologne for him Calvin Klein by perfumers Julie Massé, Ralf Schwieger and Véronique Nyberg of Mane and romantic watery florals in ETERNITY Eau Fresh for her Calvin Klein by perfumers Olivier Gillotin and Sonia Constant of Givaudan.
ETERNITY Cologne for him and ETERNITY Eau Fresh for her Calvin Klein are available for sale globally starting today on a rolling basis.
About Calvin Klein, Inc.:
CALVIN KLEIN is a global lifestyle brand that exemplifies bold, progressive ideals and a seductive aesthetic. We seek to thrill and inspire our audience while using provocative imagery and striking designs to ignite the senses.
Founded in 1968 by Calvin Klein and his business partner Barry Schwartz, we have built our reputation as a leader in American fashion through our clean aesthetic and innovative designs. Global retail sales of CALVIN KLEIN brand products exceeded $9 billion in 2019 and were distributed in over 110 countries. Calvin Klein employs over 11,500 associates globally. We were acquired by PVH Corp. in 2003.
About COTY Inc.
Coty is one of the world’s largest beauty companies with approximately $9 billion in revenue, with a purpose to celebrate and liberate the diversity of consumers’ beauty. Its strong entrepreneurial heritage has created an iconic portfolio of leading beauty brands. Coty is the global leader in fragrance, a strong number two in professional salon hair color & styling, and number three in color cosmetics. Coty operates three divisions – Coty Consumer Beauty, which is focused on color cosmetics, retail hair coloring and styling products, body care and mass fragrances sold primarily in the mass retail channels with brands such as Bourjois, Max Factor, Rimmel, Wella, Adidas and Guess; Coty Luxury, which is focused on prestige fragrances and skincare with brands such as Gucci, Hugo Boss, Calvin Klein, Chloe, Bottega Veneta and Alexander McQueen; and Coty Professional Beauty, which is focused on servicing salon owners and professionals in both hair and nail, with brands such as Wella Professionals, System Professional, OPI and ghd. Coty has approximately 20,000 colleagues globally and its products are sold in over 130 countries. Coty and its brands are committed to a range of social causes as well as seeking to minimize its impact on the environment. For additional information about Coty Inc., please visit www.coty.com .
ADVERTISING CREDITS:
Creative Direction: Calvin Klein and Mazarine
Campaign Videos: Matt Lambert
Advertising Campaign images: Lachlan Bailey
EDITORIAL CREDIT:
ETERNITY For Women Eau de Parfum CALVIN KLEIN
ETERNITY For Men Eau de toilette CALVIN KLEIN
ETERNITY Eau Fresh for her CALVIN KLEIN
ETERNITY Cologne for him CALVIN KLEIN
TVC: https://youtu.be/NN9Q2pKiDKE
SOCIAL MEDIA: #cketernity
BRAND HANDLE: @calvinklein
View source version on businesswire.com: https://www.businesswire.com/news/home/20200803005090/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom